Paul Barkofsky Email

VP, New Product Development . Vascular Therapies

Current Roles

Employees:
7
Revenue:
$703.5k
About
Vascular Therapies is a biotechnology company focused on improving patient outcomes by reducing surgical stenosis in patients with kidney and vascular disease. The company has developed Sirogen™, an investigational sirolimus formulation for local, perivascular drug delivery. Sirogen™ is currently undergoing clinical trials to determine its safety and effectiveness in improving vascular access outcomes in patients requiring an arteriovenous fistula for hemodialysis.
Vascular Therapies Address
105 Union Avenue
Cresskill, NJ
Vascular Therapies Email

Past Companies

Vascular TherapiesVice President, New Product Development
Arsenal Capital PartnersProgram Manager
CordisStaff Engineer

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.